Established · publishing since 1966Rising activity
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchCAR-T cell therapy researchViral-associated cancers and disordersUbiquitin and proteasome pathways
Publications
358
Citations
4,370
Est. group size
~13
Recurring co-author estimate
Active years
61
Publishing since 1966
In context
Among 4,953 established Medicine PIs within our index
Citations: 4,370p25 789 · p75 7,423 · cohort median 2,544
Publications / year (recent): 46.2p25 2 · p75 10.6 · cohort median 4.8
Typically publishes in teams of ~12 · 11% small-team papers (≤3 authors) · across 28 venues
Publication cadence
Publications per year over the last 10 years — averaging 46.2/year recently
Collaborators per year
Distinct co-authors at University of Michigan each year — a rough indication of whether the group around this researcher has been growing or contracting. An estimate from co-authorship, not a roster: collaborators are not necessarily lab members, and recent years can be under-counted while indexing catches up.
Recent publications
- Fixed-duration glofitamab monotherapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL) with/without prior Bruton's tyrosine kinase inhibitor (BTKi) exposure: Updated data after a 3.5-year follow-up.
Journal of Clinical Oncology · 2026
- Figure 4 from Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma
2026
- Supplemental Table 1 from Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma
2026
- Supplemental Figure 5 from Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma
2026
- Supplemental Figure 4 from Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma
2026
- Figure 7 from Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma
2026
- Supplemental Figure 7 from Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma
2026
- Figure 1 from Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma
2026
- Supplemental Figure 3 from Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma
2026
- Supplemental Figure 6 from Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma
2026
- Figure 5 from Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma
2026
- Supplemental Figure 1 from Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma
2026
- Supplemental Figure 2 from Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma
2026
- Data from Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma
2026
- Figure 3 from Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma
2026
Publishes in
- Blood×87
- Clinical Lymphoma Myeloma & Leukemia×41
- Journal of Clinical Oncology×29
- Blood Advances×13
- Hematological Oncology×13
Similar researchers
By research-topic overlap
- David A. Bond
Medicine · The Ohio State University
- Lapo Alinari
Medicine · The Ohio State University
- Beth Christian
Medicine · The Ohio State University
- Kami J. Maddocks
Medicine · The Ohio State University
- Anamarija M. Perry
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile